| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1030614602 |
| P356 | DOI | 10.1038/BJC.1995.114 |
| P932 | PMC publication ID | 2033628 |
| P698 | PubMed publication ID | 7533517 |
| P5875 | ResearchGate publication ID | 15664630 |
| P2093 | author name string | Kuitunen T | |
| Pyrhönen S | |||
| Kouri M | |||
| Nyandoto P | |||
| P2860 | cites work | Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples | Q24569561 |
| Reporting results of cancer treatment | Q29620070 | ||
| FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer | Q33363249 | ||
| Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Grou | Q33388301 | ||
| A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin | Q33421327 | ||
| High-dose MTX/5-FU and adriamycin for gastric cancer. | Q33479823 | ||
| Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer | Q34366342 | ||
| Assessment of response to therapy in advanced breast cancer | Q36068959 | ||
| Management of carcinomas of the upper gastrointestinal tract. | Q36748415 | ||
| Adenocarcinoma of the stomach: Review of 1,497 cases | Q40193432 | ||
| Phase II study of epirubicin sequential methotrexate and 5-fluorouracil for advanced colorectal cancer | Q40740454 | ||
| Chemotherapy of carcinoma of the stomach | Q40875195 | ||
| Chemotherapy for gastrointestinal cancer: new hopes or new disappointments? | Q41135182 | ||
| New developments in the treatment of gastric carcinoma | Q41872774 | ||
| Epirubicin is equivalent to adriamycin in vitro against many cancer cells but more effective against gastric cancer cells | Q54274274 | ||
| Response to doxorubicin/methotrexate/fluorouracil in advanced adenocarcinoma of pancreas or biliary tract | Q68094455 | ||
| The natural history of advanced gastric cancer | Q72051078 | ||
| Chemotherapy of advanced gastric carcinoma: to be completely rewritten? | Q72396826 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fluorouracil | Q238512 |
| methotrexate | Q422232 | ||
| P304 | page(s) | 587-591 | |
| P577 | publication date | 1995-03-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer | |
| P478 | volume | 71 |
| Q35906916 | A cost-benefit analysis of chemotherapy for gastric cancer |
| Q89953671 | A critical analysis of the cytoreductive surgery with hyperthermic intraperitoneal chemotherapy combo in the clinical management of advanced gastric cancer: an effective multimodality approach with scope for improvement |
| Q37449306 | A multi-center, phase ii clinical trial of Padexol (paclitaxel) and cisplatin for patients suffering with advanced gastric cancer |
| Q46720391 | A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer |
| Q42790798 | A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas |
| Q46435697 | A phase I study of doxifluridine combined with weekly paclitaxel for metastatic gastric cancer |
| Q36564026 | A phase I trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma |
| Q46208250 | A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer |
| Q34620042 | A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma |
| Q46172036 | A phase II study of 5-fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as first-line treatment for patients with advanced gastric cancer |
| Q33391384 | A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer |
| Q83900980 | A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Tria |
| Q33366008 | A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients |
| Q50513946 | A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer. |
| Q43202922 | A phase II study of doxifluridine and docetaxel combination chemotherapy for advanced or recurrent gastric cancer |
| Q44743198 | A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus |
| Q46601885 | A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer |
| Q46743013 | A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer |
| Q36614734 | A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer |
| Q36642170 | A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer |
| Q33379208 | A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma |
| Q46564784 | A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial |
| Q33385867 | A phase II trial of paclitaxel, 5-fluorouracil (5-FU) and cisplatin in patients with metastatic or recurrent gastric cancer |
| Q36097126 | A pilot study evaluating the safety and toxicity of epirubicin, cisplatin, and UFT (ECU regimen) in advanced gastric carcinoma |
| Q37341735 | A pilot study of cisplatin, irinotecan, leucovorin and 5-fluorouracil (PILF) combination chemotherapy for advanced gastric cancer |
| Q57805411 | A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study |
| Q38477495 | A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models |
| Q33387432 | A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer |
| Q36858273 | A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer |
| Q44923328 | A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy |
| Q57902299 | A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer |
| Q33428751 | A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer |
| Q43750753 | A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas. |
| Q39091817 | Advanced gastric adenocarcinoma: optimizing therapy options. |
| Q46052234 | Advanced or metastatic gastric cancer in elderly patients: clinicopathological, prognostic factors and treatments |
| Q36798382 | Advances in the treatment of patients with gastric adenocarcinoma. |
| Q44790691 | Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer |
| Q35640101 | Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future |
| Q36264149 | Antioxidant vitamins and chemoprevention |
| Q54686136 | Apatinib for the treatment of gastric cancer |
| Q83426498 | Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer |
| Q41823021 | Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens |
| Q51773987 | Benefit of post-operative surveillance for recurrence after curative resection for gastric cancer. |
| Q51048811 | Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. |
| Q37425848 | Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study |
| Q37475755 | Capecitabine and oxaliplatin (XELOX) for the treatment of patients with metastatic gastric cancer and severe liver dysfunction |
| Q37136996 | Capecitabine in the treatment of advanced gastric cancer |
| Q34761656 | Capecitabine or infusional 5-fluorouracil for gastroesophageal cancer: a cost-consequence analysis |
| Q38222270 | Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer |
| Q39038994 | Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety |
| Q24236634 | Chemotherapy for advanced gastric cancer |
| Q24244040 | Chemotherapy for advanced gastric cancer |
| Q38604012 | Chemotherapy for advanced gastric cancer. |
| Q34617795 | Chemotherapy for advanced gastric cancer: across the years for a standard of care |
| Q44602395 | Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study). |
| Q37446941 | Chemotherapy for advanced gastric cancer: slow but further progress |
| Q36942475 | Chemotherapy for gastric cancer patients - time for personalization in medicine? |
| Q36398226 | Chemotherapy for gastric cancer. |
| Q26768402 | Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy |
| Q37191094 | Chemotherapy for metastatic disease: review from JCOG trials |
| Q37353930 | Chemotherapy for metastatic gastric cancer in Japan |
| Q26771424 | Chemotherapy in Elderly Patients with Gastric Cancer |
| Q35108798 | Chemotherapy in gastric cancer: a review and updated meta-analysis |
| Q36694149 | Chemotherapy in metastatic gastric cancer: population-based perceptions and practice patterns of medical oncologists |
| Q61868286 | Chemotherapy of oesophago-gastric cancer |
| Q43135271 | Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer |
| Q36448668 | Clinical experiences with G17DT in gastrointestinal malignancies |
| Q83249995 | Clinical outcome of gastric cancer patients with bone marrow metastases |
| Q26828506 | Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach |
| Q41867894 | Clinical significance of chemotherapy for geriatric patients with advanced or recurrent gastric cancer |
| Q27496690 | Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis |
| Q39203436 | Clinicopathological features and outcomes of gastric cancer patients with pulmonary lymphangitis carcinomatosa |
| Q33389160 | Combination chemotherapy of heptaplatin, paclitaxel and 5-fluorouracil in patients with advanced gastric cancer: a pilot study |
| Q33631546 | Combination chemotherapy with 5-fluorouracil and heptaplatin as first-line treatment in patients with advanced gastric cancer |
| Q43542637 | Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer |
| Q36625990 | Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer |
| Q80211138 | Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer |
| Q82931090 | Combination docetaxel (Taxotere), fluorouracil, and leucovorin (TFL), as first-line chemotherapy in advanced gastric cancer: a Hellenic Cooperative Oncology Group phase II study |
| Q33912151 | Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis |
| Q53071557 | Combinatory RNA-Sequencing Analyses Reveal a Dual Mode of Gene Regulation by ADAR1 in Gastric Cancer. |
| Q35948108 | Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer |
| Q43136050 | Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis |
| Q36042902 | Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 tri |
| Q52562515 | Comparison of efficacy and tolerance between combination therapy and monotherapy as first-line chemotherapy in elderly patients with advanced gastric cancer: Study protocol for a randomized controlled trial. |
| Q55008122 | Comparison of health-related quality of life with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil chemotherapy regimens as first-line systemic therapy in locally advanced inoperable or metastatic gastric or gas |
| Q45350326 | Comparison of safety and efficacy of S-1 monotherapy and S-1 plus cisplatin therapy in elderly patients with advanced gastric cancer |
| Q87515768 | Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel |
| Q38637978 | Correlation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancer |
| Q24604411 | Critical appraisal of trastuzumab in treatment of advanced stomach cancer |
| Q37077239 | Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers. |
| Q37181813 | Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction |
| Q55033047 | Customization of therapy for gastroesophageal adenocarcinoma patients. |
| Q26774538 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer |
| Q26768296 | Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future |
| Q34413771 | DNA polymerase η protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy |
| Q43162843 | Design of precise third-line therapy for gastric cancer: target or chemotherpy? |
| Q39042851 | Dichloroacetate attenuates hypoxia-induced resistance to 5-fluorouracil in gastric cancer through the regulation of glucose metabolism |
| Q54571851 | Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. |
| Q35181089 | Docetaxel as salvage therapy in highly pretreated and drug resistant gastrointestinal carcinomas |
| Q33386661 | Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens |
| Q36616503 | Docetaxel in the treatment of gastric cancer |
| Q33396506 | Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer |
| Q44136997 | Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study. |
| Q34658209 | Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer. |
| Q38563923 | Does surgery have a role in managing incurable gastric cancer? |
| Q26764802 | Doublet Versus Single Agent as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis of 10 Randomized Controlled Trials |
| Q80179117 | Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1 |
| Q36644681 | Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer |
| Q33712779 | Effectiveness of immunochemotherapy for gastric cancer: a review of the current status |
| Q37208729 | Efficacy and safety of docetaxel plus oxaliplatin and capecitabine in the first line treatment of advanced gastric adenocarcinoma |
| Q44328704 | Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey |
| Q50285053 | Efficacy and safety study of docetaxel as salvage chemotherapy in metastatic gastric cancer failing fluoropyrimidine and platinum combination chemotherapy |
| Q33411751 | Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial |
| Q46839142 | Efficacy of S-1 plus cisplatin combination chemotherapy in patients with HER2-positive advanced gastric cancer |
| Q47771553 | Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice |
| Q43248320 | Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination |
| Q36136558 | Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer |
| Q61868327 | Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: Response, toxicity, quality of life, and survival |
| Q55338874 | Establishment and validation of prognostic nomograms in first-line metastatic gastric cancer patients. |
| Q40565520 | Etoposide, doxorubicin and cisplatin alternating with 5-fluorouracil, doxorubicin and high-dose methotrexate in patients with advanced adenocarcinoma of the stomach or the gastroesophageal junction |
| Q36613902 | Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. |
| Q26741293 | Evolution of management in peritoneal surface malignancies |
| Q37960206 | Evolving standards of care in advanced gastric cancer |
| Q89582289 | FARP1 boosts CDC42 activity from integrin αvβ5 signaling and correlates with poor prognosis of advanced gastric cancer |
| Q37362737 | FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. |
| Q91590023 | Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study |
| Q39728271 | Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Cancer: a Bayesian Network Meta-Analysis. |
| Q43264239 | Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study |
| Q79121179 | Follow-Up Surveillance for Recurrence After Curative Gastric Cancer Surgery Lacks Survival Benefit |
| Q73979376 | Gastric Cancer |
| Q34553773 | Gastric adenocarcinoma: review and considerations for future directions |
| Q36327087 | Gastric and gastro-oesophageal cancer therapy |
| Q61963099 | Gastric cancer: past progress and present challenges |
| Q42125510 | Gastric cancer: toward a cisplatin-free disease? |
| Q37697571 | Gastric peritoneal carcinomatosis - a retrospective review |
| Q46224685 | Gastrojejunostomy as induction treatment for S-1-based chemotherapy in patients with incurable gastric cancer |
| Q37522211 | Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study. |
| Q38813532 | Global chemotherapy development for gastric cancer |
| Q74241859 | Guidelines for the management of oesophageal and gastric cancer |
| Q50761028 | HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation. |
| Q53140602 | How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy?. |
| Q37815604 | Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. |
| Q33755032 | Identification of prognostic factors and surgical indications for metastatic gastric cancer |
| Q86538059 | Impact of adding cisplatin to S-1 in elderly patients with advanced gastric cancer |
| Q38447986 | Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer†. |
| Q87885346 | Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution |
| Q39937932 | In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer. |
| Q35204947 | Individualizing therapy in gastric cancer |
| Q33365431 | Infusional 5-fluorouracil and mitomycin C: an effective regimen in the treatment of advanced gastric cancer |
| Q33341264 | Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: a low cost effective regimen |
| Q24235217 | Interventions for preventing oral mucositis for patients with cancer receiving treatment |
| Q24235482 | Interventions for preventing oral mucositis for patients with cancer receiving treatment |
| Q24243046 | Interventions for preventing oral mucositis for patients with cancer receiving treatment |
| Q37703392 | Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer. |
| Q38073827 | Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers |
| Q45154773 | Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study |
| Q33349888 | Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial |
| Q42173252 | Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following failure of fluoropyrimidine-based regimens |
| Q46555285 | Irinotecan plus cisplatin combination against metastatic gastric cancer: phase II study |
| Q33400558 | Irinotecan plus mitomycin C as second-line chemotherapy for advanced gastric cancer resistant to fluoropyrimidine and Cisplatin: a retrospective study |
| Q33393276 | Irinotecan-involved regimens for advanced gastric cancer: a pooled-analysis of clinical trials |
| Q33371606 | Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). |
| Q44835243 | Is hypoalbuminemia an independent prognostic factor in patients with gastric cancer? |
| Q37589204 | Is there a role for second-line chemotherapy in advanced gastric cancer? |
| Q51568719 | Japanese gastric cancer treatment guidelines 2010 (ver. 3). |
| Q89724644 | Japanese gastric cancer treatment guidelines 2018 (5th edition) |
| Q64076485 | Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach |
| Q41898734 | Latest developments and emerging treatment options in the management of stomach cancer |
| Q50709702 | Level of hospital care and outcome of gastric cancer: a population-based evaluation of the Munich Cancer Registry. |
| Q91689831 | Liver Metastases in Newly Diagnosed Gastric Cancer: A Population-Based Study from SEER |
| Q34394426 | Liver resections in metastatic gastric cancer |
| Q35323682 | Long-Term Survival of Gastric Adenocarcinoma without Therapy: Case Report |
| Q43485654 | Long-term outcomes and prognostic factors of patients with advanced gastric cancer treated with S-1 plus cisplatin combination chemotherapy as a first-line treatment |
| Q80676121 | Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy |
| Q42285544 | Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial |
| Q87826971 | MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy |
| Q37642780 | ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer |
| Q36891375 | Management of gastric adenocarcinoma |
| Q89408585 | Management of peritoneal surface malignancies in laparoscopic era: a concise review |
| Q34175118 | Management of upper gastrointestinal cancers |
| Q36644664 | Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial |
| Q42661688 | Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. |
| Q37181422 | Measuring patient-reported outcomes in advanced gastric cancer |
| Q61868280 | Medical management of advanced gastric cancer |
| Q38527676 | Metastatic gastric cancer (MGC) patients: Can we improve survival by metastasectomy? A systematic review and meta-analysis |
| Q78311394 | Metastatic gastric cancer presenting as a solitary axillary cutaneous nodule |
| Q38087885 | Metronomic chemotherapy for cancer treatment: a decade of clinical studies |
| Q38995616 | MicroRNA-21 contributes to the discrimination of chemoresistance in metastatic gastric cancer |
| Q33413448 | Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study |
| Q33375019 | Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study |
| Q43872716 | Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC). |
| Q64097970 | Modified Epirubicin, cisplatin, and 5-FU regimen as first-line chemotherapy in metastatic gastric or gastroesophageal junction adenocarcinoma: A Phase II study |
| Q36705689 | Molecular targeted therapy for advanced gastric cancer |
| Q46616879 | Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination |
| Q36459767 | Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group |
| Q33410627 | Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study |
| Q49945586 | Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06). |
| Q42915841 | Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer |
| Q40456535 | Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer. |
| Q33932046 | Multidisciplinary approach to esophageal and gastric cancer |
| Q59330587 | Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy |
| Q43235125 | Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer |
| Q41135814 | Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients |
| Q37494644 | Novel investigational drugs for gastric cancer |
| Q37566645 | Novel targets in esophageal and gastric cancer: beyond antiangiogenesis |
| Q38139297 | Optimal chemotherapy for advanced gastric cancer: is there a global consensus? |
| Q26798400 | Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis |
| Q48673372 | Optimal indications of surgical palliation for incurable advanced gastric cancer presenting with malignant gastrointestinal obstruction |
| Q46255877 | Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study |
| Q82865577 | Outcome of surgical treatment for patients with locoregional recurrence of gastric cancer |
| Q50647977 | Outcomes in elderly patients treated with a single-agent or combination regimen as first-line chemotherapy for recurrent or metastatic gastric cancer. |
| Q38487736 | Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design |
| Q36536982 | Outcomes of third-line docetaxel-based chemotherapy in advanced gastric cancer who failed previous oxaliplatin-based and irinotecan-based chemotherapies |
| Q38244051 | Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis |
| Q37336375 | Oxaliplatin, 5-FU, folinic acid as first-line palliative chemotherapy in elderly patients with metastatic or recurrent gastric cancer |
| Q33766456 | Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) combination chemotherapy as a salvage treatment in advanced gastric cancer |
| Q34670947 | Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer |
| Q33778285 | Paclitaxel combined with capecitabine as first-line chemotherapy for advanced or recurrent gastric cancer |
| Q33356984 | Paclitaxel, carboplatin, and oral etoposide in advanced gastric adenocarcinoma: association with severe myelotoxicity |
| Q35936039 | Palliative chemotherapy for advanced gastric cancer |
| Q36516605 | Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction foll |
| Q44526173 | Palliative radiation therapy for hemorrhage of unresectable gastric cancer: a single institute experience |
| Q53213677 | Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility? |
| Q42726296 | Pharmacokinetics of paclitaxel in a hemodialysis patient with advanced gastric cancer: A case report. |
| Q37011966 | Pharmacotherapy for oesophagogastric cancer. |
| Q43013465 | Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer. |
| Q46699254 | Phase I dose-escalating study of 24-h continuous infusion of 5-fluorouracil in combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer |
| Q24810562 | Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer |
| Q85026066 | Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer |
| Q43236141 | Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer |
| Q42863444 | Phase I study of Paclitaxel, Cisplatin and 5-fluorouracil combination chemotherapy for unresectable / recurrent gastric cancer |
| Q36611262 | Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. |
| Q46683166 | Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer |
| Q43080282 | Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer. |
| Q24649684 | Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer |
| Q36977421 | Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma |
| Q34507843 | Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma |
| Q60697885 | Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients |
| Q33341045 | Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer |
| Q33385128 | Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer |
| Q36673543 | Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer |
| Q36614109 | Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer |
| Q36615597 | Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma |
| Q46822414 | Phase I/II study of a combination of S-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer |
| Q35949510 | Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer |
| Q45054366 | Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer |
| Q40388526 | Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer. |
| Q46707260 | Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002). |
| Q33364558 | Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy |
| Q36614248 | Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer |
| Q37336356 | Phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with recurrent or metastatic gastric cancer |
| Q83834873 | Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer |
| Q37222473 | Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer |
| Q33386875 | Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). |
| Q42986070 | Phase II study of oxaliplatin, UFT, and leucovorin in patients with metastatic gastric cancer |
| Q46175387 | Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens |
| Q36853997 | Phase II study of paclitaxel, cisplatin, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer |
| Q56776529 | Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer |
| Q42032242 | Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer |
| Q46287658 | Phase II study of weekly paclitaxel by one-hour infusion for advanced gastric cancer |
| Q83782142 | Phase II study of weekly paclitaxel, cisplatin, and 5-fluorouracil for advanced gastric cancer |
| Q35037527 | Placebo effects in oncology |
| Q37651342 | Postgastrectomy follow-up in the West: evidence base, guidelines, and daily practice |
| Q37701587 | Precise integrin-targeting near-infrared imaging-guided surgical method increases surgical qualification of peritoneal carcinomatosis from gastric cancer in mice |
| Q45921145 | Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients. |
| Q44076876 | Preoperative assessment of peritoneal carcinomatosis: intraindividual comparison of 18F-FDG PET/CT and MRI. |
| Q36791086 | Primary extraosseous Ewing sarcoma of the lung in children |
| Q41242339 | Profiling chemotherapy-associated myelotoxicity among Chinese gastric cancer population receiving cytotoxic conventional regimens: epidemiological features, timing, predictors and clinical impacts |
| Q44365791 | Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen). |
| Q51046395 | Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer. |
| Q53559950 | Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. |
| Q39778923 | Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials |
| Q43206575 | Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer |
| Q46595662 | Protective effects of a mixture of antioxidant vitamins and minerals on the genotoxicity of doxorubicin in somatic cells of Drosophila melanogaster |
| Q50962533 | Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy. |
| Q40060365 | Quality of life with biweekly docetaxel and capecitabine in advanced gastro-oesophageal cancer |
| Q73379733 | Raltitrexed (Tomudex) in combination with platinum-based agents and/or anthracyclines: preliminary results of phase I clinical trials |
| Q36616011 | Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer |
| Q35927364 | Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. |
| Q53604465 | Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. |
| Q36396339 | Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. |
| Q44441494 | Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer |
| Q64109947 | Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing r |
| Q34389753 | Recent advances in chemotherapy for advanced gastric cancer |
| Q37719335 | Recent advances in chemotherapy for advanced gastric cancer in Japan |
| Q36376439 | Recent developments in the systemic therapy of advanced gastroesophageal malignancies |
| Q34590788 | Recent developments in the treatment of gastric carcinoma |
| Q35445166 | Refining docetaxel-containing therapy for gastric cancer. |
| Q36615965 | Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. |
| Q43067439 | Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer |
| Q37609793 | Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer |
| Q33729150 | Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer |
| Q42170790 | Retrospective evaluation of sequential outpatient chemotherapy for advanced gastric cancer |
| Q59134275 | Retrospective study of oxaliplatin, leucovarin and 5 fluoruracil regimen in patients with advanced gastric cancer with poor performance status: A study at a tertiary center of South India |
| Q37052880 | Review of docetaxel in the treatment of gastric cancer |
| Q41597654 | Review: chemotherapy, irradiation and their roles in the management of oesophageal cancer |
| Q77942693 | Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil |
| Q33416469 | S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil |
| Q56517475 | S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil |
| Q34588472 | S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial |
| Q44064732 | S-1 plus oxaliplatin vs. S-1 as first-line treatment in patients with previously untreated advanced gastric cancer: a randomized phase II study |
| Q33415440 | S-1-based versus 5-FU-based chemotherapy as first-line treatment in advanced gastric cancer: a meta-analysis of randomized controlled trials |
| Q42364212 | Safe use of capecitabine-cisplatin in metastatic gastric carcinoma with severe liver dysfunction: a case report from Algeria |
| Q37815444 | Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer |
| Q33366124 | Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer |
| Q37992841 | Second-line chemotherapy for advanced gastric cancer in Korea |
| Q38750633 | Second-line chemotherapy for patients with advanced gastric cancer. |
| Q36964966 | Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? |
| Q26778027 | Second-line treatment of metastatic gastric cancer: Current options and future directions |
| Q36153493 | Self-Expandable Metallic Stent Placement in Malignant Gastric Outlet Obstruction: A Comparison Between 2 Brands of Stents |
| Q44665743 | Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy |
| Q35995868 | Sequential irinotecan hydrochloride/S-1 for S-1-resistant inoperable gastric cancer: A feasibility study |
| Q60932024 | Should S-1 be better than capecitabine for patients with advanced gastric cancer in Asia? A systematic review and meta-analysis |
| Q34782021 | Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? |
| Q44681408 | Significance of palliative gastrectomy for late-stage gastric cancer patients |
| Q33357475 | Single-Agent Irinotecan as Second-Line Treatment for Advanced Gastric Cancer |
| Q35095365 | Status of treatment for advanced gastric carcinoma |
| Q34608899 | Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer |
| Q24246675 | Supportive care for patients with gastrointestinal cancer |
| Q43996295 | Surgical complications in gastric cancer patients preoperatively treated with chemotherapy: their risk factors and clinical relevance |
| Q90321326 | Surgical management of metastatic gastric cancer: moving beyond the guidelines |
| Q38031998 | Surgical treatment of liver metastases of gastric cancer: state of the art. |
| Q39234296 | Survival after failure of first-line chemotherapy in advanced gastric cancer patients: differences between Japan and the rest of the world |
| Q84178293 | Survival analysis of stage IV metastatic gastric cancer patients treated with HangAm-Plus |
| Q92617822 | Survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: a systematic review |
| Q44012763 | Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912. |
| Q40300376 | Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines |
| Q46589174 | Systemic chemotherapy of TS-1 and cisplatin for gastric signet-ring cell carcinoma presenting as cardiac tamponade |
| Q54504807 | TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. |
| Q64100306 | Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer |
| Q35000785 | Targeting metastatic upper gastrointestinal adenocarcinomas |
| Q51812919 | Thalidomide combined with chemotherapy in treating elderly patients with advanced gastric cancer. |
| Q38941416 | The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis |
| Q33577629 | The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone |
| Q53087621 | The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015. |
| Q94526793 | The Prognostic Value of Neutrophil-to-lymphocyte Ratio and Monocyte-to-lymphocyte Ratio in Metastatic Gastric Cancer Treated with Systemic Chemotherapy |
| Q42930809 | The addition of pravastatin to chemotherapy in advanced gastric carcinoma: A randomised phase II trial |
| Q37400028 | The changing use of palliative chemotherapy for recurrent esophagogastric cancer: a single center retrospective 15-year review. |
| Q38116772 | The diagnostic value of monoclonal gastric cancer 7 antigen: a systematic review with meta-analysis |
| Q34086875 | The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer |
| Q40383915 | The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma |
| Q36193781 | The efficacy and toxicity of paclitaxel plus S-1 compared with paclitaxel plus 5-FU for advanced gastric cancer: a PRISMA systematic review and meta-analysis of randomized controlled trials. |
| Q37477047 | The efficacy of paclitaxel and cisplatin combination chemotherapy for the treatment of metastatic or recurrent gastric cancer: a multicenter phase II study |
| Q33437413 | The efficiency and safety of trastuzumab for advanced gastric and gastroesophageal cancer: a meta-analysis of five randomized controlled trials |
| Q44108051 | The evaluation of surgical treatment for gastric cancer patients with noncurative resection |
| Q44898596 | The prognostic significance of chemotherapy for stage IV gastric cancer patients: a single-institution experience |
| Q37427269 | The progress of targeted therapy in advanced gastric cancer |
| Q35139161 | The role of chemotherapy in the current treatment of gastric cancer |
| Q64105131 | The role of surgery and radiation in advanced gastric cancer: A population-based study of Surveillance, Epidemiology, and End Results database |
| Q36097240 | The role of taxanes in the management of gastroesphageal cancer |
| Q37731949 | The significance of multi-line chemotherapy for advanced gastric cancer: A retrospective analysis |
| Q46817815 | The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma. |
| Q38201470 | The treatment of peritoneal carcinomatosis in advanced gastric cancer: state of the art. |
| Q50996446 | The value of palliative gastrectomy in gastric cancer with distant metastasis. |
| Q33818002 | Third-line chemotherapy in advanced gastric cancer: A systematic review and meta-analysis |
| Q33407797 | Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer |
| Q35875892 | Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy |
| Q38467530 | Three-week combination chemotherapy with S-1 and cisplatin as first-line treatment in patients with advanced gastric cancer: a retrospective study with 159 patients |
| Q43193739 | Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer |
| Q33903541 | Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel |
| Q37633540 | Trastuzumab for gastric cancer |
| Q27851578 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial |
| Q36220464 | Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer |
| Q90749501 | Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer |
| Q37895575 | Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity |
| Q45218658 | Treatment of patients with advanced gastric cancer: experience from an Indian tertiary cancer center |
| Q53579494 | Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin-based regimen: two parallel randomized phase II studies. |
| Q34661367 | Treatment options in patients with metastatic gastric cancer: current status and future perspectives |
| Q55379237 | Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study. |
| Q33631305 | Treatment-related severe and fatal adverse events with molecular targeted agents in the treatment of advanced gastric cancer: a meta-analysis |
| Q34000663 | Vitamin C enhances anticancer activity in methotrexate‑treated Hep3B hepatocellular carcinoma cells |
| Q40315009 | Weekly Taxotere and cisplatin with continuous-infusion 5-fluoruracil for the treatment of advanced gastric and esophageal cancer: a prospective, observational, single-institution experience. |
| Q33387696 | Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin |
| Q39682966 | What is the reference cytotoxic regimen for advanced gastric cancer: standard versus optimal therapy? |
| Q73315349 | [Oncology '96] |
| Q86578814 | [Treatment of gastric cancer] |
Search more.